Literature DB >> 7280993

Vitreous hemorrhage complicating retinal astrocytic hamartoma.

A J Kroll, D P Ricker, R M Robb, D M Albert.   

Abstract

Tuberous sclerosis classically presents a triad of mental deficiency, seizures and adenoma sebaceum. Among the ocular manifestations are astrocytic hamartomas in the retina. This paper describes the case of a 24-year-old man with tuberous sclerosis who had recurrent vitreous hemorrhage from a large epipapillary astrocytic hamartoma in the left eye. Pars plana vitrectomy cleared the vitreous and bimanual bipolar coagulation of tumor bleeding points was done. Fragments of the friable tumor were obtained with the vitrectomy instrument and were prepared for tissue culture, histology, and electron microscopy. Although pars plana vitrectomy offers certain advantages over other methods of biopsy, it does present a danger of extraocular seeding of malignant cells; therefore, it is not recommended in cases with probable intraocular malignancy.

Entities:  

Mesh:

Year:  1981        PMID: 7280993     DOI: 10.1016/0039-6257(81)90123-5

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  4 in total

1.  THE MULBERRY TUMOUR (A Case Report).

Authors:  S S Mann; M Deshpande; N Kapoor
Journal:  Med J Armed Forces India       Date:  2017-06-27

2.  Glial tumors of the retina. The 2009 King Khaled Memorial Lecture.

Authors:  Jerry A Shields; Carol L Shields
Journal:  Saudi J Ophthalmol       Date:  2009-10-24

3.  A Case of Proliferative Retinopathy Complicated with Tuberous Sclerosis Treated by Vitreous Surgery.

Authors:  Emika Nemoto; Seita Morishita; Mari Akashi; Ryohsuke Kohmoto; Masanori Fukumoto; Hiroyuki Suzuki; Takatoshi Kobayashi; Teruyo Kida; Jun Sugasawa; Tsunehiko Ikeda
Journal:  Case Rep Ophthalmol       Date:  2016-12-01

4.  Primary ocular presentation of tuberous sclerosis - A case report.

Authors:  Nancy M Rajasekaran; Saban Horo; Thomas Kuriakose
Journal:  Indian J Ophthalmol       Date:  2019-03       Impact factor: 1.848

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.